BR9712198A - Compostos de ácido carboxílico de 2-amino substituído com 3-acoxiisoxazol-4il preparação farmacêutica e utilização de tal composto - Google Patents

Compostos de ácido carboxílico de 2-amino substituído com 3-acoxiisoxazol-4il preparação farmacêutica e utilização de tal composto

Info

Publication number
BR9712198A
BR9712198A BR9712198-3A BR9712198A BR9712198A BR 9712198 A BR9712198 A BR 9712198A BR 9712198 A BR9712198 A BR 9712198A BR 9712198 A BR9712198 A BR 9712198A
Authority
BR
Brazil
Prior art keywords
group
carboxylic acid
amino carboxylic
disease
alkyl
Prior art date
Application number
BR9712198-3A
Other languages
English (en)
Inventor
Benny Bang-Andersen
Klaus Peter Bogeso
Povl Krogsgaard-Larsen
Sibylle Moltzen Lenz
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of BR9712198A publication Critical patent/BR9712198A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D275/00—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings
    • C07D275/02—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings
    • C07D275/03—Heterocyclic compounds containing 1,2-thiazole or hydrogenated 1,2-thiazole rings not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/12—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
    • C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
    • C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
    • C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<B>"COMPOSTO DE áCIDO CARBOXìLICO DE 2-AMINO SUBSTITUìDO COM 3-ACOXIISOXAZOL-4-IL; PREPARAçãO FARMACEUTICA E UTILIZAçãO DE TAL COMPOSTO"<D>. Derivados de ácido carboxílico de 2-amino substituído com (3-Alcoxiisoxazol-4-il) e análogos de enxofre dos mesmos possuindo a fórmula geral (I) ou (II), onde R~ 1~, é hidrogênio, alcil, alcenil, alcinil, cicloalc(en)il, cicloalc(en)il-alc(en/in)il, ou fenilalc(en/in)il opcionalmente substituído; A é uma união ou um grupo espaçador hidrocarbono; B é um grupo -CR~ a~(NR~ b~R~ c~)-COOR~ 5~ onde R~ a~-R~ c~ são independentemente hidrogênio ou alcil, e R~ c~ é definido como R~ 1~ ou pivaloxiloximetil, ou B é um grupo de fórmula (III), onde R~ 2~, R~ 3~ e R~ 4~ são independentemente selecionados de hidrogênio, um grupo hidrocarbono não aromático, fenil- e tienil-alcil, e um grupo alifático, ou R~ 3~e R~ 4~ são conectados, assim formando um grupo alcileno, alcenileno ou alcinileno, ou R~ 4~ e R~ 2~ são conectados a fim de formar um grupo alcileno, alcenileno ou alcinileno, opcionalmente substituído com hidróxi ou metil, ou a fim de formar CH~ 2~-O-CH~ 2~; E é COOR~ 6~, onde R~ 6~ é definido como R~ 5~, ou E é um tetrazol ou tetrazoil; X é O ou S; e Y é O ou S; são aminoácidos excitatórios (EAA), em particular, ligandos receptores de AMPA e/ou NMDA, úteis no tratamento de isquemia cerebral, doença de Huntington, distúrbios epilépticos, doença de Parkinson, doença de Alzheimer, esquizofrenia, dor, depressão e ansiedade.
BR9712198-3A 1996-10-04 1997-10-03 Compostos de ácido carboxílico de 2-amino substituído com 3-acoxiisoxazol-4il preparação farmacêutica e utilização de tal composto BR9712198A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK109296 1996-10-04
PCT/DK1997/000426 WO1998015542A1 (en) 1996-10-04 1997-10-03 3-alkoxyisoxazol-4-yl-substituted 2-amino carboxylic acid compounds

Publications (1)

Publication Number Publication Date
BR9712198A true BR9712198A (pt) 1999-08-31

Family

ID=8100908

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9712198-3A BR9712198A (pt) 1996-10-04 1997-10-03 Compostos de ácido carboxílico de 2-amino substituído com 3-acoxiisoxazol-4il preparação farmacêutica e utilização de tal composto

Country Status (26)

Country Link
US (1) US6200999B1 (pt)
EP (1) EP0934286B1 (pt)
JP (1) JP2001501630A (pt)
KR (1) KR20000048908A (pt)
CN (1) CN1238766A (pt)
AR (1) AR008880A1 (pt)
AT (1) ATE230734T1 (pt)
AU (1) AU733004B2 (pt)
BG (1) BG103348A (pt)
BR (1) BR9712198A (pt)
CA (1) CA2268028C (pt)
CZ (1) CZ116899A3 (pt)
DE (1) DE69718338T2 (pt)
EA (1) EA001625B1 (pt)
ES (1) ES2189978T3 (pt)
HU (1) HUP0000084A3 (pt)
IL (1) IL129135A0 (pt)
IS (1) IS5009A (pt)
NO (1) NO312961B1 (pt)
NZ (1) NZ334798A (pt)
PL (1) PL332553A1 (pt)
SK (1) SK42899A3 (pt)
TR (1) TR199900724T2 (pt)
UA (1) UA52698C2 (pt)
WO (1) WO1998015542A1 (pt)
ZA (1) ZA978877B (pt)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA73749C2 (en) * 1999-11-01 2005-09-15 Diarylenines
JP4052573B2 (ja) * 2000-09-15 2008-02-27 バーテックス ファーマシューティカルズ インコーポレイテッド イソオキサゾールおよびｅｒｋのインヒビターとしてのその使用
US20040106794A1 (en) * 2001-04-16 2004-06-03 Schering Corporation 3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
UA78529C2 (en) 2001-10-10 2007-04-10 Wyeth Corp Derivatives of [[2-(amino-3,4-dioxo-1-cyclobutene-1-yl)amino]alkyl] acid for treating pain
US20040152694A1 (en) * 2003-02-04 2004-08-05 Istvan Kurucz Methods and compositions for treating inflammatory disorders of the airways
CN1863810B (zh) 2003-04-09 2010-12-01 惠氏公司 [2-(8，9-二氧代-2，6-二氮杂二环[5.2.0]壬-1(7)-烯-2-基)烷基]膦酸衍生物及其作为n-甲基-d-天冬氨酸(nmda)受体拮抗剂的应用
TW200514775A (en) 2003-10-22 2005-05-01 Wyeth Corp Methods for the preparation of {2-[(8,9)-dioxo-2,6-diaza-bicyclo[5.2.0]-non-1(7)-en-2-yl]ethyl} phosphonic acid and esters thereof
CA2625301A1 (en) * 2005-10-11 2007-04-19 F. Hoffmann-La Roche Ag Isoxazole derivatives
US8722714B2 (en) 2008-01-16 2014-05-13 The Honk Kong University of Science and Technology Oxazolidine derivatives as NMDA antagonists
EP2338492A1 (en) 2009-12-24 2011-06-29 Universidad del Pais Vasco Methods and compositions for the treatment of alzheimer
TW201609719A (zh) * 2014-05-28 2016-03-16 美國禮來大藥廠 作為ＴＡＲＰ－γ８依賴性ＡＭＰＡ受體拮抗劑之６－經取代－３Ｈ－１，３－苯并噻唑－２－酮化合物
EP3406595B1 (en) * 2016-01-21 2020-04-01 Agro-Kanesho Co., Ltd. Method for producing 2-aminonicotinic acid benzyl ester derivative

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69102816T2 (de) 1990-05-11 1995-03-16 Sankyo Co Piperdinyloxy- und Chinindidinyloxy- isoxazol- Derivate, ihre Herstellung und ihre therapeutische Verwendung.
DE69325662T2 (de) 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon Dopamin rezeptor subtyp liganden
DK124393D0 (da) * 1993-11-03 1993-11-03 Lundbeck & Co As H Compounds

Also Published As

Publication number Publication date
EP0934286A1 (en) 1999-08-11
NO991561D0 (no) 1999-03-30
ATE230734T1 (de) 2003-01-15
CA2268028A1 (en) 1998-04-16
BG103348A (en) 1999-11-30
WO1998015542A1 (en) 1998-04-16
US6200999B1 (en) 2001-03-13
HUP0000084A3 (en) 2001-12-28
EA199900358A1 (ru) 1999-10-28
DE69718338T2 (de) 2003-10-16
SK42899A3 (en) 1999-08-06
AR008880A1 (es) 2000-02-23
AU4451797A (en) 1998-05-05
NO312961B1 (no) 2002-07-22
CA2268028C (en) 2003-03-18
DE69718338D1 (de) 2003-02-13
IS5009A (is) 1999-03-23
KR20000048908A (ko) 2000-07-25
PL332553A1 (en) 1999-09-13
HUP0000084A2 (hu) 2000-06-28
ES2189978T3 (es) 2003-07-16
EA001625B1 (ru) 2001-06-25
JP2001501630A (ja) 2001-02-06
NZ334798A (en) 2000-06-23
IL129135A0 (en) 2000-02-17
UA52698C2 (uk) 2003-01-15
CZ116899A3 (cs) 1999-09-15
AU733004B2 (en) 2001-05-03
CN1238766A (zh) 1999-12-15
EP0934286B1 (en) 2003-01-08
NO991561L (no) 1999-06-04
TR199900724T2 (xx) 1999-06-21
ZA978877B (en) 1998-04-17

Similar Documents

Publication Publication Date Title
BR9712198A (pt) Compostos de ácido carboxílico de 2-amino substituído com 3-acoxiisoxazol-4il preparação farmacêutica e utilização de tal composto
DE60113514T2 (de) 2-oxo-1-pyrrolidinderivate, verfahren zu ihrer herstellung und ihre verwendung
RU2002124522A (ru) Производные 2-оксо-1-пирролидина, способ их получения и применения
NO180540C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktiv cyklisk amidderivat
CN101490002A (zh) 作为止痛剂的3-氧代异二氢吲哚-1-甲酰胺衍生物
IL140042A0 (en) Carboxylic acids and carboxylic acid isosteres of n-heterocyclic compounds
DE3884555D1 (de) Octahydronaphthalenoxim-derivate fuer cholesterolsynthese-inhibierung, verfahren fuer deren herstellung und diese enthaltende zusammenstellungen.
ATE64391T1 (de) Azacyclische verbindungen, verfahren zu ihrer herstellung und ihre verwendung als pharmazeutisches mittel.
EP3831810A1 (en) Benzene derivative
EP0309424A3 (en) New amidino derivatives
ATE159029T1 (de) Phosphonsäurederivate, verfahren zur herstellung und ihre verwendung
EP0543919A1 (en) USE OF HETEROCYCLIC AMINO ALCOHOL COMPOUNDS FOR THE TREATMENT OF CNS DISEASES.
MXPA06003748A (es) Compuestos de lactama condensada.
BR0113348A (pt) Pró-drogas para ligantes de receptores de nmda
KR910020023A (ko) 헤테로사이클릭-nmda길항제
WO2000027378A3 (en) Cystine derivatives as therapeutic agents for matrix metalloprotease related diseases
KR930000527A (ko) 칼슘-길항성 물질로서의 이노시톨 포스페이트 동족체
DE69124025D1 (de) Organosilan-Derivate, diese enthaltende pharmazeutische Mittel und Verfahren zu ihrer Herstellung
DE69310524T2 (de) Phosphono substituierte tetrazol-derivate
CN101747253B (zh) 三取代的手性内酰胺类衍生物及其制备方法和用途
BR0206533A (pt) Composto, composição farmacêutica, e, uso de um composto
WO2004094396A3 (en) Dihydrothiazine prodrugs of thiazolium agents
DE60303288D1 (de) Mmp-inhibitoren

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.